In vitro evaluation of antimicrobial resistance selection in Neisseria gonorrhoeae

Allen, George P.; Deao, Kristina M.; Hill, Stéphanie; Schipelliti, Sandra M.; Tran, Thomas

doi:10.1016/j.ijantimicag.2021.106417

Cited by 4 publications

(2 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent study suggested that the use of Gen for gonococcal infections would likely lead to emergence of resistance, although the potential mechanisms for this were not discussed ( 34 ). To understand how low-level Gen R may arise, in two separate experiments, we selected and screened (see Materials and Methods) for spontaneous mutants of the Gen-susceptible N. gonorrhoeae strain FA19 (Gen MIC = 8 μg/mL) which could grow on gonococcal base (GCB) agar containing 1× Gen MIC; these colonies arose at frequencies ranging from 1.5 × 10 −8 to 5.2 × 10 −7 .…”

Section: Resultsmentioning

confidence: 99%

A Single Amino Acid Substitution in Elongation Factor G Can Confer Low-Level Gentamicin Resistance in Neisseria gonorrhoeae

Holley

Dhulipala

Balthazar

et al. 2022

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

A Single Amino Acid Substitution in Elongation Factor G Can Confer Low-Level Gentamicin Resistance in Neisseria gonorrhoeae

Holley

Dhulipala

Balthazar

et al. 2022

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…The MPC was determined according to the standard agar dilution method [ 26 , 27 , 28 ]. A bacterial suspension (10 10 CFU/mL) was plated (100 μL) on agar plates with various drug concentrations (0, 1, 2, 4, 8, 16, and 64 × MIC) and incubated at 37 °C for 24 h. The initial provisional mutant prevention concentration (MPCpr) was defined as the lowest drug concentration that inhibited colony growth after 24 h. Subsequently, drug concentrations were decreased by 20% from MPCpr to prepare agar plates for further MPC determination.…”

Section: Methodsmentioning

confidence: 99%

Halicin: A New Horizon in Antibacterial Therapy against Veterinary Pathogens

Wang,

Zhao,

Chen

et al. 2024

Antibiotics

View full text Add to dashboard Cite

It is crucial to discover novel antimicrobial drugs to combat resistance. This study investigated the antibacterial properties of halicin (SU3327), an AI-identified anti-diabetic drug, against 13 kinds of common clinical pathogens of animal origin, including multidrug-resistant strains. Employing minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) assessments, halicin demonstrated a broad-spectrum antibacterial effect. Time-killing assays revealed its concentration-dependent bactericidal activity against Escherichia coli ATCC 25922 (E. coli ATCC 25922), Staphylococcus aureus ATCC 29213 (S. aureus ATCC 29213), and Actinobacillus pleuropneumoniae S6 (APP S6) after 4 h of treatment at concentrations above the MIC. Halicin exhibited longer post-antibiotic effects (PAEs) and sub-MIC effects (PA-SMEs) for E. coli 25922, S. aureus 29213, and APP S6 compared to ceftiofur and ciprofloxacin, the commonly used veterinary antimicrobial agents, indicating sustained antibacterial action. Additionally, the results of consecutive passaging experiments over 40 d at sub-inhibitory concentrations showed that bacteria exhibited difficulty in developing resistance to halicin. Toxicology studies confirmed that halicin exhibited low acute toxicity, being non-mutagenic, non-reproductive-toxic, and non-genotoxic. Blood biochemical results suggested that halicin has no significant impact on hematological parameters, liver function, and kidney function. Furthermore, halicin effectively treated respiratory A. pleuropneumoniae infections in murine models. These results underscore the potential of halicin as a new antibacterial agent with applications against clinically relevant pathogens in veterinary medicine.

show abstract

The resistance mechanisms of bacteria against ciprofloxacin and new approaches for enhancing the efficacy of this antibiotic

Shariati

Arshadi

Khosrojerdi

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

For around three decades, the fluoroquinolone (FQ) antibiotic ciprofloxacin has been used to treat a range of diseases, including chronic otorrhea, endocarditis, lower respiratory tract, gastrointestinal, skin and soft tissue, and urinary tract infections. Ciprofloxacin's main mode of action is to stop DNA replication by blocking the A subunit of DNA gyrase and having an extra impact on the substances in cell walls. Available in intravenous and oral formulations, ciprofloxacin reaches therapeutic concentrations in the majority of tissues and bodily fluids with a low possibility for side effects. Despite the outstanding qualities of this antibiotic, Salmonella typhi, Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa have all shown an increase in ciprofloxacin resistance over time. The rise of infections that are resistant to ciprofloxacin shows that new pharmacological synergisms and derivatives are required. To this end, ciprofloxacin may be more effective against the biofilm community of microorganisms and multi-drug resistant isolates when combined with a variety of antibacterial agents, such as antibiotics from various classes, nanoparticles, natural products, bacteriophages, and photodynamic therapy. This review focuses on the resistance mechanisms of bacteria against ciprofloxacin and new approaches for enhancing its efficacy.

show abstract

In vitro evaluation of antimicrobial resistance selection in Neisseria gonorrhoeae

Cited by 4 publications

References 33 publications

A Single Amino Acid Substitution in Elongation Factor G Can Confer Low-Level Gentamicin Resistance in Neisseria gonorrhoeae

A Single Amino Acid Substitution in Elongation Factor G Can Confer Low-Level Gentamicin Resistance in Neisseria gonorrhoeae

Halicin: A New Horizon in Antibacterial Therapy against Veterinary Pathogens

The resistance mechanisms of bacteria against ciprofloxacin and new approaches for enhancing the efficacy of this antibiotic

Contact Info

Product

Resources

About